Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axonyx Inc.

This article was originally published in Start Up

Executive Summary

Axonyx is offering a portfolio of second-generation Alzheimer's therapeutics.

You may also be interested in...



Alzheimer's Disease: A disease in search of a drug

We're still in the iron lung age of Alzheimer's treatment. When the new Jonas Salk comes along, ideas will change dramatically.

Oxagen Ltd.

Oxagen's goal is to use large familial clinical groups and sample banks to identify disease genes through agreements with three groups of academic clinical investigators, located throughout Europe.

polyGenomics Inc.

PolyGenomics was spun-out of Yale University to develop a genetic amplification technology in the search for genes implicated in psychiatric illnesses.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel